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Introduction
　Irinotecan (CPT-11), a camptothecin analog with potent 
anticancer activity by the inhibition of topoisomerase I, is 
applied for a broad spectrum of solid tumors, including col-
orectal, lung, and gastric cancer [1]. However, it causes side-
effects such as severe diarrhea and neutropenia in 20-35% of 
patients [2]. Irinotecan is metabolized by carboxylesterase to 
form an active metabolite, 7-ethyl-10-hydroxycamptothecin 
(SN-38), which is subsequently conjugated by UDP-
glucuronosyltransferase 1A1 (UGT1A1) [3]. 
　Polymorphism of the UGT1A1 gene is known to play an 
important role in irinotecan pharmacokinetics and severe 
toxicity [4]. Here we describe severe toxicity in a patient 
with UGT1A1*6 genotypes after chemoradiotherapy includ-
ing irinotecan.
Clinical summary
　The patient was a 71-year-old man with a heavy smoking 
history, in whom an abnormal shadow was noted on chest 
images. He was admitted to our hospital for further examina-
tion and management of the shadow. Chest radiography and 
a computed tomography (CT) scan demonstrated a nodule 
on the right S3 and enlarged mediastinal lymph node. The 
patient was diagnosed with lung cancer (squamous cell car-
cinoma cT2aN3M0 stage IIIB) with an ECOG performance 
status (PS) of 1 based on transbronchial lung biopsy and sys-
temic workups. He received chemotherapy consisting of iri-
notecan (50mg/m2 on days 1, 8 and 15) and cisplatin (60mg/
m2 on day 1) with concurrent thoracic radiotherapy, which 
confirmed feasibility [5]. A chart of his body temperature 
and white blood cells is shown in Figure 1. Because he had 
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a high fever and severe toxicity after day 7, all treatments 
were discontinued. During the first cycle, grade 4 leukope-
nia, grade 4 neutropenia, grade 3 febrile neutropenia, grade 
4 thrombocytopenia, and grade 2 diarrhea developed accord-
ing to the Common Terminology Criteria for Adverse Events 
Version 3.0 (CTCAE v3.0). Myelotoxicity peaked on day 12 
with white blood cells 200/µl, neutrophils 12/µl, and plate-
lets 9,000/µl, respectively. These life-threatening toxicities 
persisted and PS fell to 4. The patient was treated with gran-
ulocyte-colony stimulating factor and cefepime antibiotic, 
and was given a platelet transfusion. His status resolved on 
day 19 after intensive care. He then intended to move to an-
other hospital for supportive care. We obtained his consent 
to perform genetic testing, and he was found to have UG-
T1A1*6 heterozygous and UGT1A1*28 wild-type gene 
polymorphisms.
Discussion
　SN-38, an active metabolite of irinotecan, is detoxified by 
glucuronidation with UGT1A isoforms, 1A1, 1A7, 1A9, and 
1A10. Clinical pharmacogenomic studies of irinotecan were 
conducted in cancer patients. Lyer revealed that patients 
with the UGT1A1*28 polymorphism had a significantly 
lower SN-38 glucuronidation rate than those with the normal 
allele and suffered more severe diarrhea and neutropenia [6]. 
Innocenti revealed that homozygosity for UGT1A1*28 and 
total bilirubin levels are strongly associated with severe neu-
tropenia and could be used to identify cancer patients predis-
posed to the severe toxicity of irinotecan [7]. Therefore, 
UGT1A1*28 polymorphisms were taken into consideration 
by the US Food and Drug Administration (FDA) as predic-
tors of irinotecan toxicity in 2005. However, the distribution 
of polymorphisms shows large interethnic differences. The 
frequency of UGT1A1*28 is high in Caucasians, whereas it 
is low in Asians [8]. 
　In Asian studies, UGT1A1*6 allele is associated with low 
glucuronidation activity and severe toxicity. Minami ana-
lyzed Japanese cancer patients treated with irinotecan for as-
sociation between genetic polymorphisms and toxicities and 
demonstrated that homozygotes and double heterozygotes of 
*6 and *28 were significantly associated with severe neutro-
penia [9]. Incidences of grade 3 or 4 neutropenia for patients 
with wild, heterozygous, and homozygous of UGT1A1*6 or 
*28 were 14.3% (3/21), 24.1% (7/29), and 80.0%(4/5) in iri-
notecan monotherapy and 57.1%(20/35), 70.0%(14/20), and 
100%(7/7) in irinotecan with cisplatin therapy, respectively. 
Han demonstrated homozygosity for UGT1A1*6 was asso-
ciated with a high risk of severe neutropenia during irinote-
can treatment [10]. Incidences of grade 4 neutropenia for 
patients with wild or heterozygous, and homozygous of UG-
T1A1*6 were 24%(18/75), and 67%(4/6), respectively. On-



























Figure 1. Chart of body temperature (solid line) and white blood cells (dashed line). D, appearance of diarrhea. 
Plt, platelet transfusion. G-CSF, daily hypodermic injection of granulocyte colony-stimulating factor. 
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associated with a high risk of severe neutropenia [11]. Inci-
dences of grade 3 or 4 neutropenia for patients with wild, 
heterozygous, and homozygous of UGT1A1*6 were 
11%(9/70), 35%(17/48), and 50%(3/3), respectively. Al-
though UGT1A1*6 homozygosity is associated with severe 
toxicity, its frequency is low. In three papers [12-14], 212 
Japanese patients were analyzed for UGT1A1*28 and *6. 
The frequency of *6/*6, *28/*28 and *6/*28 was only 2.8%, 
3.3% and 1.9%, respectively, whereas *6/- was 26.4%. In 
the present case, a patient heterozygous for UGT1A1*6 ex-
perienced life-threatening toxicity involving neutropenia, 
thrombocytopenia, febrile neutropenia and diarrhea after iri-
notecan plus cisplatin chemotherapy. In our prospective 
phase II study and recent meta-analysis of Asian patients, 
UGT1A1*6 polymorphism including homozygotes and 
heterozygotes was associated with severe neutropenia [15, 
16]. Considering the frequency and the present severe case, 
we should use irinotecan carefully for patients with UG-
T1A1*6 heterozygous polymorphism. There might be an ad-
ditional unknown factor. Regarding efficacy, Han reported 
an association with UGT1A1 polymorphism that patients 
with UGT1A1*6/*6 had a lower tumor response, and shorter 
progression-free and overall survival [10]. In the present 
case, the patient refused to continue chemotherapy or radio-
therapy after recovery and transferred to supportive care. 
Markedly severe toxicity led to decreased therapeutic effi-
cacy.  
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